The CRTD is set up as an interdisciplinary and interconnected network of 13 research groups in the core center and over 90 principal investigators from seven research institutes in Dresden. At the moment, there are four professors and nine group leaders researching at the CRTD. CRTD members are located in the Biotechnology Center (BIOTEC) of the TU Dresden, the Max Planck Institute of Molecular Cell Biology and Genetics, the Max Bergmann Center of Biomaterials, clinical departments of the University Hospital 'Carl Gustav Carus', or the Medical Theoretical Center. In addition, 18 companies support the CRTD network. This network provides the expertise to develop novel regenerative therapies fast and efficiently.

Started January 1, 2006 as the DFG Center for Regenerative Therapies Dresden, the CRTD became the Cluster of Excellence “From cells to tissues to therapies: Engineering the cellular basis of regeneration” of the Technische Universität Dresden on October 13, 2006. In June 2012, the CRTD was approved again as DFG Research Center and Cluster of Excellence.

Information material about the CRTD

The flyer “From cells to tissues to therapies: Engineering the cellular basis of regeneration“ give a short review about the CRTD in English. Here you could download it.

The image brochure "Five for Life" gives a detailed description of the research, partners, research groups, and acitvities of the CRTD in German. Please download a lower resolution file here.

The Activity Report presents the development of the CRTD from 2009 to 2010 in English. Each research group describes their research. Further details are shown in the areas teaching, activities, and public relations. Please download it here.

Film about the CRTD

(made by the Deutsche Forschungsgemeinschaft)

Film about Biotechnology

Jim Greenwood, CEO of the International Biotechnology Organisation: Why I work in biotech

Why is Biotechnology important? What can it do for humankind? Hear the opinion of Jim Greenwood, president of the International Biotechnology Organisation (BIO) about why he got involved in biotechnology after years of public service as a member of congress in the U.S.